CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: ZNF320 (ImmuneEditome ID:162967)

1. Gene summary of enriched editing regions for ZNF320

check button Gene summary
Gene informationGene symbol

ZNF320

Gene ID

162967

GeneSynonymsZFPL
GeneCytomap

19q13.41

GeneTypeprotein-coding
GeneDescriptionzinc finger protein 320|zinc finger gene 320|zinc finger protein like
GeneModificationdate20230518
UniprotIDA2RRD8;A0A669KBJ2;M0R0Z8;M0QZA2;M0R2L4;M0QX96;M0R1K6
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr19:52866667-52868433:-ENST00000595202.4ENSG00000182986.11ZNF320ncRNA_intronicAluSg,AluSz,MLT1A0,(TTAA)n,AluSz6,AluSq,AluSpchr19:52866667-52868433:-.alignment
chr19:52866667-52868433:-ENST00000598199.1ENSG00000182986.11ZNF320ncRNA_intronicAluSg,AluSz,MLT1A0,(TTAA)n,AluSz6,AluSq,AluSpchr19:52866667-52868433:-.alignment
chr19:52876554-52877094:-ENST00000600930.1ENSG00000182986.11ZNF320ncRNA_exonicAluJb,AluSx1chr19:52876554-52877094:-.alignment
chr19:52878276-52878916:-ENST00000598199.1ENSG00000182986.11ZNF320ncRNA_intronicAluY,HSMAR2,AluJbchr19:52878276-52878916:-.alignment
chr19:52878276-52878916:-ENST00000600930.1ENSG00000182986.11ZNF320ncRNA_intronicAluY,HSMAR2,AluJbchr19:52878276-52878916:-.alignment
chr19:52880041-52880529:-ENST00000600930.1ENSG00000182986.11ZNF320ncRNA_intronicAluSc8,L1M3,AluSzchr19:52880041-52880529:-.alignment
chr19:52882584-52885129:-ENST00000600930.1ENSG00000182986.11ZNF320ncRNA_intronicAluSx1,AluSc8,AluSg4,MLT1A0,AluSq2,AluSz,AluSz6,AluSxchr19:52882584-52885129:-.alignment
chr19:52886855-52887665:-ENST00000600930.1ENSG00000182986.11ZNF320ncRNA_intronicAluSz,(GAAG)n,A-richchr19:52886855-52887665:-.alignment
chr19:52895194-52896714:-ENST00000596215.1ENSG00000182986.11ZNF320ncRNA_exonicAluSq10,AluJb,AluSx1,AluSp,(TTTA)nchr19:52895194-52896714:-.alignment


Top

2. Tumor-specific enriched editing regions for ZNF320


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
chr19:52880041-52880529:-BRCAEER1.1726e-02image
ENSG00000182986.11,ZNF320HNSCEAG1.6070e-02image
chr19:52880041-52880529:-KICHEER2.9847e-02image
chr19:52878276-52878916:-KIRCEER2.5736e-05image
chr19:52880041-52880529:-KIRCEER2.2967e-04image
ENSG00000182986.11,ZNF320KIRCEAG4.2613e-03image
chr19:52878276-52878916:-KIRPEER2.6129e-02image
chr19:52878276-52878916:-LUADEER1.1380e-02image
ENSG00000182986.11,ZNF320LUADEAG8.0489e-03image
chr19:52878276-52878916:-THCAEER5.0519e-03image
chr19:52880041-52880529:-THCAEER3.6415e-04image
ENSG00000182986.11,ZNF320THCAEAG9.1620e-03image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot
chr19:52878276-52878916:-KICHPathEER2.3145e-031.1011e-030.4048image
ENSG00000182986.11,ZNF320KICHPathEAG2.0905e-023.0716e-020.2704image
chr19:52878276-52878916:-KIRPCliEER2.0586e-028.5009e-030.1904image
chr19:52876554-52877094:-KIRPCliEER8.7134e-045.9279e-050.2963image
ENSG00000182986.11,ZNF320KIRPCliEAG1.0380e-032.5681e-040.2609image
ENSG00000182986.11,ZNF320READPathEAG4.3413e-022.5029e-02-0.2166image
chr19:52880041-52880529:-TGCTPathEER4.0256e-021.5773e-02-0.2836image
ENSG00000182986.11,ZNF320THCAPathEAG3.6746e-072.1827e-050.1890image
chr19:52880041-52880529:-THCAPathEER2.3414e-036.1239e-030.1342image
chr19:52876554-52877094:-THCAPathEER7.3286e-042.5563e-020.1038image


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot
chr19:52882584-52885129:-ESCAEER4.0900e-024.7623e-023.2710e+02image

Top

3. Enriched editing regions and immune related genes for ZNF320


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr19:52876554-52877094:-BLCAEERENSG00000180257,ZNF816-0.41081.3437e-106.1104e-13-0.4080imageNNNAT_cells_CD4_memory_activatedGSVA_HALLMARK_UV_RESPONSE_UP
chr19:52876554-52877094:-GBMEERENSG00000104835,SARS2-0.50576.2059e-073.9246e-08-0.4328imageNNNAMonocytesGSVA_HALLMARK_APOPTOSIS
chr19:52876554-52877094:-GBMEERENSG00000204514,ZNF814-0.49841.0904e-062.7051e-08-0.4375imageNNNAMonocytesGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr19:52876554-52877094:-GBMEERENSG00000182986,ZNF320-0.48353.2370e-064.8726e-09-0.4579imageNNNAMonocytesGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY
chr19:52876554-52877094:-GBMEERENSG00000105136,ZNF419-0.48173.2811e-066.6537e-08-0.4262imageNNNAMonocytesGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr19:52876554-52877094:-GBMEERENSG00000117877,CD3EAP-0.48173.6280e-069.5062e-09-0.4501imageNNCD3EAPMacrophages_M0GSVA_HALLMARK_MYC_TARGETS_V2
chr19:52876554-52877094:-GBMEERENSG00000186017,ZNF566-0.46309.6645e-062.7725e-08-0.4372imageNNNAMonocytesGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY
chr19:52876554-52877094:-GBMEERENSG00000101452,DHX35-0.45821.2333e-054.5837e-08-0.4309imageNNNAMonocytesGSVA_HALLMARK_COAGULATION
chr19:52876554-52877094:-GBMEERENSG00000124193,SRSF6-0.45161.8848e-051.2794e-07-0.4177imageNNNAMonocytesGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr19:52876554-52877094:-GBMEERENSG00000171649,ZIK1-0.44003.8509e-052.8504e-07-0.4070imageNNNAMonocytesGSVA_HALLMARK_G2M_CHECKPOINT
chr19:52878276-52878916:-BLCAEERENSG00000182986,ZNF320-0.47395.0756e-182.7073e-23-0.4903imageNELAVL1;FBLNAT_cells_regulatory_(Tregs)GSVA_HALLMARK_UV_RESPONSE_UP
chr19:52878276-52878916:-BLCAEERENSG00000213801,ZNF816-ZNF321P-0.42034.9505e-141.1195e-17-0.4294imageNNNAT_cells_regulatory_(Tregs)GSVA_HALLMARK_UV_RESPONSE_UP
chr19:52878276-52878916:-BLCAEERENSG00000180257,ZNF816-0.38846.1702e-121.6562e-15-0.4022imageNELAVL1;FBL;NOP58NAT_cells_CD4_memory_activatedGSVA_HALLMARK_UV_RESPONSE_UP
chr19:52878276-52878916:-BLCAEERENSG00000170954,ZNF415-0.35915.9086e-102.0679e-15-0.4009imageNELAVL1;FBL;NOP58NAT_cells_CD4_memory_activatedGSVA_HALLMARK_MYC_TARGETS_V2
chr19:52878276-52878916:-LGGEERENSG00000180198,RCC1-0.46734.8060e-241.0650e-22-0.4181imageNELAVL1;FBL;NOP58NAT_cells_CD4_memory_restingGSVA_HALLMARK_E2F_TARGETS
chr19:52878276-52878916:-LGGEERENSG00000196214,ZNF766-0.46073.0703e-231.4186e-27-0.4590imageNELAVL1;FBL;NOP58NAT_cells_CD4_naiveGSVA_HALLMARK_E2F_TARGETS
chr19:52878276-52878916:-LGGEERENSG00000170892,TSEN34-0.45884.8635e-231.0160e-24-0.4357imageNELAVL1;FBL;NOP58NAT_cells_CD4_naiveGSVA_HALLMARK_DNA_REPAIR
chr19:52878276-52878916:-LGGEERENSG00000213024,NUP62-0.45661.0808e-225.2404e-27-0.4545imageNELAVL1;FBL;NOP58NUP62T_cells_CD4_naiveGSVA_HALLMARK_G2M_CHECKPOINT
chr19:52878276-52878916:-LGGEERENSG00000065978,YBX1-0.44672.3839e-221.7290e-23-0.4251imageNELAVL1;FBL;NOP58YBX1T_cells_CD4_naiveGSVA_HALLMARK_MYC_TARGETS_V1
chr19:52878276-52878916:-LGGEERENSG00000198830,HMGN2-0.45223.0488e-222.6611e-21-0.4052imageNELAVL1;FBL;NOP58HMGN2T_cells_CD4_naiveGSVA_HALLMARK_E2F_TARGETS
chr19:52878276-52878916:-BLCAEERENSG00000182986,ZNF320-0.47395.0756e-182.7073e-23-0.4903imageNELAVL1;FBLNAT_cells_regulatory_(Tregs)GSVA_HALLMARK_UV_RESPONSE_UP
chr19:52878276-52878916:-BLCAEERENSG00000213801,ZNF816-ZNF321P-0.42034.9505e-141.1195e-17-0.4294imageNNNAT_cells_regulatory_(Tregs)GSVA_HALLMARK_UV_RESPONSE_UP
chr19:52878276-52878916:-BLCAEERENSG00000180257,ZNF816-0.38846.1702e-121.6562e-15-0.4022imageNELAVL1;FBL;NOP58NAT_cells_CD4_memory_activatedGSVA_HALLMARK_UV_RESPONSE_UP
chr19:52878276-52878916:-BLCAEERENSG00000170954,ZNF415-0.35915.9086e-102.0679e-15-0.4009imageNELAVL1;FBL;NOP58NAT_cells_CD4_memory_activatedGSVA_HALLMARK_MYC_TARGETS_V2
chr19:52878276-52878916:-LGGEERENSG00000180198,RCC1-0.46734.8060e-241.0650e-22-0.4181imageNELAVL1;FBL;NOP58NAT_cells_CD4_memory_restingGSVA_HALLMARK_E2F_TARGETS
chr19:52878276-52878916:-LGGEERENSG00000196214,ZNF766-0.46073.0703e-231.4186e-27-0.4590imageNELAVL1;FBL;NOP58NAT_cells_CD4_naiveGSVA_HALLMARK_E2F_TARGETS
chr19:52878276-52878916:-LGGEERENSG00000170892,TSEN34-0.45884.8635e-231.0160e-24-0.4357imageNELAVL1;FBL;NOP58NAT_cells_CD4_naiveGSVA_HALLMARK_DNA_REPAIR
chr19:52878276-52878916:-LGGEERENSG00000213024,NUP62-0.45661.0808e-225.2404e-27-0.4545imageNELAVL1;FBL;NOP58NUP62T_cells_CD4_naiveGSVA_HALLMARK_G2M_CHECKPOINT
chr19:52878276-52878916:-LGGEERENSG00000065978,YBX1-0.44672.3839e-221.7290e-23-0.4251imageNELAVL1;FBL;NOP58YBX1T_cells_CD4_naiveGSVA_HALLMARK_MYC_TARGETS_V1
chr19:52878276-52878916:-LGGEERENSG00000198830,HMGN2-0.45223.0488e-222.6611e-21-0.4052imageNELAVL1;FBL;NOP58HMGN2T_cells_CD4_naiveGSVA_HALLMARK_E2F_TARGETS
chr19:52880041-52880529:-BLCAEERENSG00000180257,ZNF816-0.41571.6109e-111.2948e-14-0.4222imageNNNAT_cells_CD4_memory_activatedGSVA_HALLMARK_UV_RESPONSE_UP
chr19:52880041-52880529:-BLCAEERENSG00000182986,ZNF320-0.37513.1256e-095.3355e-15-0.4278imageNDHX9NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_UV_RESPONSE_UP
chr19:52880041-52880529:-GBMEERENSG00000171295,ZNF440-0.48443.6496e-061.1557e-07-0.4243imageNDHX9NAMonocytesGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr19:52880041-52880529:-GBMEERENSG00000182986,ZNF320-0.48364.9535e-063.5314e-08-0.4396imageNDHX9NAMonocytesGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY
chr19:52880041-52880529:-GBMEERENSG00000196705,ZNF431-0.46161.1220e-056.7204e-07-0.4002imageNDHX9NAMonocytesGSVA_HALLMARK_XENOBIOTIC_METABOLISM
chr19:52880041-52880529:-GBMEERENSG00000263002,ZNF234-0.46321.5036e-052.4312e-07-0.4144imageNDHX9NAMonocytesGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY
chr19:52880041-52880529:-GBMEERENSG00000171466,ZNF562-0.45831.7931e-054.2859e-07-0.4065imageNDHX9NAMonocytesGSVA_HALLMARK_XENOBIOTIC_METABOLISM
chr19:52880041-52880529:-GBMEERENSG00000213762,ZNF134-0.45572.3304e-051.7744e-07-0.4186imageNNNAMonocytesGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING
chr19:52880041-52880529:-GBMEERENSG00000167232,ZNF91-0.44144.7557e-055.3951e-07-0.4033imageNDHX9NAMonocytesGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY
chr19:52880041-52880529:-GBMEERENSG00000236060,HSPB1P10.39363.1938e-041.4929e-070.4209imageNNNAT_cells_CD4_memory_activatedGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY

More results



Top

4. Enriched editing regions and immune related splicing for ZNF320


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr19:52880041-52880529:-
COADEERMEXENSG00000150991.10chr12124911647:124911822:124911952:124912180:124912734:124913092:124913320:1249137740.25324.0537e-027.4541e-110.4337imageNNNADendritic_cells_activatedGSVA_HALLMARK_XENOBIOTIC_METABOLISM
ENSG00000182986.11,ZNF320
COADEAGMEXENSG00000110321.11chr1110798991:10799113:10799212:10799305:10799551:10799756:10800089:10800348-0.27237.3917e-039.9982e-18-0.5105imageNADAR;AIFM1;ALYREF;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;EIF4A3;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LARP4B;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MOV10;MSI2;NONO;NOP56;NPM1;PRPF8;PTBP1;RBFOX2;RBM22;RBM27;RBM47;RTCB;SAFB2;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;TAF15;TARBP2;TARDBP;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184NANeutrophilsGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION
ENSG00000182986.11,ZNF320
COADEAGMEXENSG00000185043.6chr1590231356:90231507:90232218:90232427:90232978:90233703:90233834:902340470.24842.2212e-021.2394e-130.4494imageNADAR;AIFM1;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX54;DGCR8;EIF4A3;ELAVL1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LARP4B;LIN28;LIN28B;LSM11;MOV10;MSI2;NONO;NOP56;NPM1;PRPF8;PTBP1;RBFOX2;RBM22;RBM27;RTCB;SLTM;SMNDC1;SND1;SRSF1;SRSF3;TAF15;TARDBP;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YWHAG;ZNF184CIB1Dendritic_cells_activatedGSVA_HALLMARK_P53_PATHWAY
ENSG00000182986.11,ZNF320
COADEAGMEXENSG00000145495.10chr510394752:10394785:10397292:10397307:10400783:10400842:10402058:10402139-0.23593.5096e-025.3762e-14-0.4554imageNADAR;AIFM1;ALYREF;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;EIF4A3;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPM;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LARP4B;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MOV10;MSI2;NONO;NOP56;NPM1;PRPF8;PTBP1;RBFOX2;RBM22;RBM27;RBM47;RTCB;SAFB2;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;TAF15;TARBP2;TARDBP;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184NADendritic_cells_activatedGSVA_HALLMARK_INFLAMMATORY_RESPONSE
ENSG00000182986.11,ZNF320
COADEAGIRENSG00000135392.11chr1255820959:55823189:55823401:558235080.22984.9635e-021.6438e-120.4303imageNADAR;AIFM1;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;EIF4A3;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI2;NONO;NOP56;NPM1;PRPF8;PTBP1;RBFOX2;RBM27;RBM47;SAFB2;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;TAF15;TARDBP;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184NAMast_cells_activatedGSVA_HALLMARK_UV_RESPONSE_UP
ENSG00000182986.11,ZNF320
COADEAGMEXENSG00000160714.5chr1154551459:154551492:154551770:154551819:154551819:154551979:154552092:154552183-0.23204.3084e-022.9717e-14-0.4595imageNAIFM1;ALYREF;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;EIF4A3;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LARP4B;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MOV10;MSI2;NONO;NOP56;NPM1;PRPF8;PTBP1;RBFOX2;RBM22;RBM47;SAFB2;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;TAF15;TARDBP;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184NAEosinophilsGSVA_HALLMARK_P53_PATHWAY
ENSG00000182986.11,ZNF320
COADEAGIRENSG00000005436.9chr275662705:75670284:75671949:756720160.23613.6544e-023.8931e-150.4741imageNADAR;AIFM1;ALYREF;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;EIF4A3;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LIN28;LIN28B;LSM11;MOV10;MSI2;NONO;NOP56;NPM1;PRPF8;PTBP1;RBFOX2;RBM22;RBM27;RBM47;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;TAF15;TARDBP;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;ZNF184NAEosinophilsGSVA_HALLMARK_DNA_REPAIR
ENSG00000182986.11,ZNF320
COADEAGMEXENSG00000160741.12chr1153947677:153948329:153948457:153948644:153952017:153952262:153952396:153952446-0.26071.2677e-022.5158e-16-0.4918imageNADAR;AIFM1;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;EIF4A3;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LARP4B;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI2;NONO;NOP56;NPM1;PRPF8;PTBP1;RBFOX2;RBM22;RBM27;RTCB;SAFB2;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;TAF15;TARDBP;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184NANeutrophilsGSVA_HALLMARK_DNA_REPAIR
ENSG00000182986.11,ZNF320
COADEAGMEXENSG00000138041.11chr255568193:55568363:55573618:55573777:55579678:55579781:55581566:55581698-0.23393.7138e-027.7391e-11-0.4009imageNNNAEosinophilsGSVA_HALLMARK_P53_PATHWAY
ENSG00000182986.11,ZNF320
COADEAGMEXENSG00000100644.12chr1461736889:61737109:61738086:61738373:61740542:61741188:61744704:617448130.23563.7629e-024.3982e-120.4227imageNADAR;AIFM1;ALYREF;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;EIF4A3;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LARP4B;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MOV10;MSI2;NONO;NOP56;PRPF8;PTBP1;RBFOX2;RBM22;RBM27;RBM47;SAFB2;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;TAF15;TARBP2;TARDBP;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184HIF1ADendritic_cells_activatedGSVA_HALLMARK_DNA_REPAIR

More results



Top

5. Enriched editing regions and immune infiltration for ZNF320


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chr19:52878276-52878916:-ACCEERT_cells_CD84.2471e-02-0.2628image
ENSG00000182986.11,ZNF320ACCEAGT_cells_CD81.5885e-02-0.2894image
chr19:52876554-52877094:-BLCAEERMacrophages_M11.6695e-030.1848image
chr19:52878276-52878916:-BLCAEERMacrophages_M15.4436e-060.2364image
chr19:52880041-52880529:-BLCAEERT_cells_CD4_memory_activated2.4969e-040.2083image
chr19:52882584-52885129:-BLCAEERMonocytes2.4066e-030.3002image
ENSG00000182986.11,ZNF320BLCAEAGT_cells_CD4_memory_activated4.2575e-040.1803image
chr19:52876554-52877094:-BRCAEERB_cells_naive1.3976e-02-0.0783image
chr19:52878276-52878916:-BRCAEERMacrophages_M23.6583e-030.0902image
chr19:52880041-52880529:-BRCAEERNK_cells_activated1.7447e-090.1923image
chr19:52895194-52896714:-BRCAEERT_cells_follicular_helper1.5344e-020.2507image
ENSG00000182986.11,ZNF320BRCAEAGB_cells_naive4.4035e-03-0.0872image
chr19:52878276-52878916:-CESCEERMast_cells_activated2.5116e-02-0.1793image
ENSG00000182986.11,ZNF320CESCEAGDendritic_cells_resting3.4355e-020.1614image
chr19:52876554-52877094:-CHOLEERMacrophages_M12.8712e-020.3810image
chr19:52878276-52878916:-CHOLEERT_cells_regulatory_(Tregs)2.2499e-02-0.4022image
ENSG00000182986.11,ZNF320CHOLEAGT_cells_regulatory_(Tregs)1.6133e-02-0.4096image
chr19:52876554-52877094:-COADEERMacrophages_M15.2570e-030.2463image
chr19:52878276-52878916:-COADEERNK_cells_resting1.3154e-02-0.1709image
chr19:52880041-52880529:-COADEERDendritic_cells_activated6.8979e-030.1877image
chr19:52895194-52896714:-COADEERDendritic_cells_activated9.7959e-030.5627image
ENSG00000182986.11,ZNF320COADEAGDendritic_cells_activated7.3043e-050.2501image
chr19:52878276-52878916:-DLBCEERMast_cells_activated1.4113e-030.5738image
ENSG00000182986.11,ZNF320DLBCEAGNeutrophils1.0187e-040.6498image
chr19:52876554-52877094:-ESCAEERMacrophages_M01.8488e-040.3802image
chr19:52878276-52878916:-ESCAEERT_cells_regulatory_(Tregs)1.0873e-02-0.2262image
chr19:52880041-52880529:-ESCAEERT_cells_CD4_memory_resting8.6560e-03-0.2397image
chr19:52882584-52885129:-ESCAEERT_cells_follicular_helper3.1802e-030.5561image
chr19:52895194-52896714:-ESCAEERT_cells_CD83.5909e-030.3389image
ENSG00000182986.11,ZNF320ESCAEAGMacrophages_M01.9980e-050.3633image
chr19:52876554-52877094:-GBMEERMonocytes4.5586e-040.2846image
chr19:52878276-52878916:-GBMEERT_cells_CD82.4455e-020.1790image
chr19:52880041-52880529:-GBMEERT_cells_gamma_delta3.4851e-03-0.2419image
ENSG00000182986.11,ZNF320GBMEAGT_cells_CD81.5879e-020.1898image
chr19:52876554-52877094:-HNSCEEREosinophils2.8794e-02-0.2446image
chr19:52878276-52878916:-HNSCEEREosinophils6.4165e-03-0.2053image
chr19:52880041-52880529:-HNSCEERNeutrophils5.9896e-03-0.2398image
ENSG00000182986.11,ZNF320HNSCEAGEosinophils7.5705e-04-0.2351image
chr19:52878276-52878916:-KICHEERDendritic_cells_resting8.1063e-030.3334image
chr19:52880041-52880529:-KICHEERT_cells_CD4_memory_activated1.5404e-040.4732image
ENSG00000182986.11,ZNF320KICHEAGT_cells_CD82.3231e-020.2834image
chr19:52876554-52877094:-KIRCEEREosinophils1.0017e-030.1686image
chr19:52878276-52878916:-KIRCEEREosinophils4.7327e-02-0.1017image
chr19:52880041-52880529:-KIRCEERT_cells_CD4_naive7.1804e-050.2028image
chr19:52882584-52885129:-KIRCEERT_cells_CD4_memory_resting2.4783e-05-0.4452image
ENSG00000182986.11,ZNF320KIRCEAGEosinophils1.7460e-160.4037image
chr19:52876554-52877094:-KIRPEERMacrophages_M14.0633e-040.2202image
chr19:52878276-52878916:-KIRPEERMacrophages_M11.0518e-020.1555image
chr19:52880041-52880529:-KIRPEERT_cells_CD81.4876e-030.2023image
chr19:52882584-52885129:-KIRPEERT_cells_CD4_memory_activated2.4372e-02-0.2598image
chr19:52895194-52896714:-KIRPEERT_cells_CD4_memory_activated1.2273e-040.4024image
ENSG00000182986.11,ZNF320KIRPEAGB_cells_naive5.6430e-040.2070image
chr19:52878276-52878916:-LAMLEERMonocytes8.4829e-030.3215image
ENSG00000182986.11,ZNF320LAMLEAGDendritic_cells_activated1.7497e-020.2486image
chr19:52876554-52877094:-LGGEERB_cells_naive1.4121e-02-0.1114image
chr19:52878276-52878916:-LGGEERT_cells_CD4_naive1.6680e-040.1671image
chr19:52880041-52880529:-LGGEERT_cells_CD4_naive7.1749e-050.1977image
ENSG00000182986.11,ZNF320LGGEAGB_cells_memory1.0026e-040.1691image
chr19:52876554-52877094:-LIHCEERNK_cells_resting1.0299e-030.3022image
chr19:52878276-52878916:-LIHCEERPlasma_cells1.2600e-030.2799image
chr19:52880041-52880529:-LIHCEERT_cells_regulatory_(Tregs)3.7629e-020.2508image
ENSG00000182986.11,ZNF320LIHCEAGMast_cells_activated8.4587e-040.2706image
chr19:52876554-52877094:-LUADEERT_cells_CD4_memory_activated1.1449e-060.2577image
chr19:52878276-52878916:-LUADEERDendritic_cells_resting7.6279e-03-0.1270image
chr19:52880041-52880529:-LUADEERMacrophages_M26.7853e-03-0.1369image
ENSG00000182986.11,ZNF320LUADEAGT_cells_CD4_memory_resting5.8490e-030.1266image
chr19:52876554-52877094:-LUSCEEREosinophils2.2100e-030.2126image
chr19:52878276-52878916:-LUSCEERMacrophages_M12.2501e-02-0.1313image
chr19:52880041-52880529:-LUSCEERMast_cells_resting3.9268e-03-0.1737image
chr19:52882584-52885129:-LUSCEERT_cells_CD85.1461e-030.5321image
chr19:52895194-52896714:-LUSCEERDendritic_cells_activated1.2262e-020.5132image
ENSG00000182986.11,ZNF320LUSCEAGT_cells_CD4_memory_activated9.2950e-040.1809image
chr19:52876554-52877094:-MESOEERMonocytes9.7920e-03-0.3394image
chr19:52878276-52878916:-MESOEERT_cells_gamma_delta7.1103e-030.3213image
ENSG00000182986.11,ZNF320MESOEAGT_cells_gamma_delta2.0877e-020.2664image
chr19:52876554-52877094:-OVEERT_cells_regulatory_(Tregs)1.3200e-020.1526image
chr19:52878276-52878916:-OVEERT_cells_CD81.2033e-030.1922image
chr19:52880041-52880529:-OVEERB_cells_memory4.0148e-030.1836image
chr19:52882584-52885129:-OVEERMonocytes2.3314e-020.3028image
ENSG00000182986.11,ZNF320OVEAGT_cells_CD89.5751e-030.1527image
chr19:52878276-52878916:-PAADEERT_cells_CD4_naive1.7389e-020.1902image
chr19:52880041-52880529:-PAADEERMacrophages_M21.7828e-02-0.2067image
ENSG00000182986.11,ZNF320PAADEAGDendritic_cells_activated2.6005e-030.2302image
chr19:52876554-52877094:-PCPGEERT_cells_gamma_delta7.6809e-050.3102image
chr19:52880041-52880529:-PCPGEERDendritic_cells_resting1.8358e-020.2482image
ENSG00000182986.11,ZNF320PCPGEAGT_cells_gamma_delta9.0462e-040.2501image
chr19:52876554-52877094:-PRADEERMacrophages_M01.0455e-03-0.1524image
chr19:52878276-52878916:-PRADEERMacrophages_M23.6896e-020.0948image
chr19:52880041-52880529:-PRADEERNK_cells_resting6.8043e-040.1696image
ENSG00000182986.11,ZNF320PRADEAGPlasma_cells1.0000e-03-0.1473image
chr19:52878276-52878916:-READEERDendritic_cells_resting1.7714e-020.2613image
ENSG00000182986.11,ZNF320READEAGT_cells_follicular_helper4.5095e-020.2142image
chr19:52876554-52877094:-SARCEERNK_cells_resting5.0428e-03-0.2076image
chr19:52880041-52880529:-SARCEERMacrophages_M11.5720e-020.1950image
ENSG00000182986.11,ZNF320SARCEAGNK_cells_resting7.0077e-03-0.1774image
chr19:52876554-52877094:-SKCMEERMacrophages_M24.3679e-04-0.2315image
chr19:52878276-52878916:-SKCMEERDendritic_cells_activated4.1435e-02-0.1209image
chr19:52880041-52880529:-SKCMEERT_cells_CD88.3453e-040.2113image
ENSG00000182986.11,ZNF320SKCMEAGT_cells_CD85.5096e-030.1563image
chr19:52876554-52877094:-STADEERT_cells_CD84.6915e-040.2255image
chr19:52880041-52880529:-STADEERT_cells_CD4_memory_resting1.4850e-02-0.1403image
chr19:52882584-52885129:-STADEERNeutrophils1.8093e-040.5646image
chr19:52895194-52896714:-STADEERT_cells_CD81.3430e-020.1850image
ENSG00000182986.11,ZNF320STADEAGT_cells_CD4_memory_resting5.9731e-03-0.1517image
chr19:52878276-52878916:-TGCTEERNeutrophils4.4401e-050.3356image
chr19:52880041-52880529:-TGCTEERT_cells_regulatory_(Tregs)2.8220e-030.2542image
ENSG00000182986.11,ZNF320TGCTEAGT_cells_follicular_helper2.0199e-02-0.1870image
chr19:52876554-52877094:-THCAEERMacrophages_M21.6911e-03-0.1452image
chr19:52878276-52878916:-THCAEERMast_cells_activated2.7931e-020.1006image
chr19:52880041-52880529:-THCAEERT_cells_regulatory_(Tregs)5.7011e-030.1352image
ENSG00000182986.11,ZNF320THCAEAGDendritic_cells_resting1.9532e-030.1383image
chr19:52878276-52878916:-THYMEERMacrophages_M16.7837e-030.2718image
chr19:52880041-52880529:-THYMEERB_cells_memory4.7610e-03-0.3486image
ENSG00000182986.11,ZNF320THYMEAGDendritic_cells_resting1.4895e-02-0.2348image
chr19:52876554-52877094:-UCECEERT_cells_CD4_memory_activated3.9610e-020.1666image
chr19:52878276-52878916:-UCECEERDendritic_cells_activated1.0177e-020.1990image
chr19:52880041-52880529:-UCECEERT_cells_CD81.0338e-020.2184image
ENSG00000182986.11,ZNF320UCECEAGT_cells_regulatory_(Tregs)3.7676e-02-0.1582image
chr19:52876554-52877094:-UCSEERT_cells_CD4_memory_resting3.1080e-02-0.3218image
ENSG00000182986.11,ZNF320UCSEAGT_cells_CD4_memory_activated3.2298e-020.2945image
chr19:52876554-52877094:-UVMEERT_cells_CD4_naive3.9674e-02-0.4140image
ENSG00000182986.11,ZNF320UVMEAGT_cells_CD4_naive7.3897e-03-0.3859image


Top

6. Enriched editing regions and immune gene sets for ZNF320


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot
chr19:52880041-52880529:-BLCAEER3.5957e-02image5.5167e-040.1967image
chr19:52876554-52877094:-BLCAEER1.5719e-02image1.6580e-030.1849image


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot
ENSG00000182986.11,ZNF320BLCAEAG6.6596e-050.20365.6872e-030.14201.7659e-030.16034.6466e-030.1453image


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
chr19:52876554-52877094:-ACCGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEER4.4364e-02-0.2650image
ENSG00000182986.11,ZNF320ACCGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEAG9.7801e-03-0.3090image
chr19:52878276-52878916:-ACCGSVA_HALLMARK_DNA_REPAIREER2.8109e-02-0.2836image
ENSG00000182986.11,ZNF320BLCAGSVA_HALLMARK_IL6_JAK_STAT3_SIGNALINGEAG1.4150e-050.2213image
chr19:52878276-52878916:-BLCAGSVA_HALLMARK_IL6_JAK_STAT3_SIGNALINGEER2.2169e-100.3255image
chr19:52882584-52885129:-BLCAGSVA_HALLMARK_ESTROGEN_RESPONSE_LATEEER4.9559e-030.2789image
chr19:52880041-52880529:-BLCAGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER9.9522e-080.2993image
chr19:52895194-52896714:-BLCAGSVA_HALLMARK_APICAL_SURFACEEER1.6093e-020.3531image
chr19:52876554-52877094:-BLCAGSVA_HALLMARK_COMPLEMENTEER7.0113e-050.2325image
ENSG00000182986.11,ZNF320BRCAGSVA_HALLMARK_GLYCOLYSISEAG2.8029e-060.1430image
chr19:52878276-52878916:-BRCAGSVA_HALLMARK_FATTY_ACID_METABOLISMEER1.1771e-050.1356image
chr19:52880041-52880529:-BRCAGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER1.0379e-190.2868image
chr19:52876554-52877094:-BRCAGSVA_HALLMARK_GLYCOLYSISEER5.3864e-070.1590image
chr19:52878276-52878916:-CESCGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER1.2531e-020.1995image
chr19:52880041-52880529:-CESCGSVA_HALLMARK_P53_PATHWAYEER1.6744e-030.2772image
chr19:52876554-52877094:-CESCGSVA_HALLMARK_COMPLEMENTEER7.3957e-030.2530image
ENSG00000182986.11,ZNF320CESCGSVA_HALLMARK_COMPLEMENTEAG3.1894e-040.2713image
chr19:52876554-52877094:-CHOLGSVA_HALLMARK_DNA_REPAIREER8.8849e-03-0.4483image
chr19:52878276-52878916:-CHOLGSVA_HALLMARK_ANGIOGENESISEER2.3512e-020.3995image
chr19:52880041-52880529:-CHOLGSVA_HALLMARK_MITOTIC_SPINDLEEER3.9413e-02-0.3914image
chr19:52876554-52877094:-COADGSVA_HALLMARK_PROTEIN_SECRETIONEER1.1228e-050.3788image
ENSG00000182986.11,ZNF320COADGSVA_HALLMARK_DNA_REPAIREAG6.0972e-04-0.2170image
chr19:52878276-52878916:-COADGSVA_HALLMARK_ADIPOGENESISEER4.7447e-040.2391image
chr19:52880041-52880529:-COADGSVA_HALLMARK_DNA_REPAIREER1.3179e-02-0.1725image
chr19:52895194-52896714:-COADGSVA_HALLMARK_P53_PATHWAYEER3.2834e-020.4785image
chr19:52880041-52880529:-ESCAGSVA_HALLMARK_P53_PATHWAYEER1.3016e-020.2271image
chr19:52882584-52885129:-ESCAGSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALINGEER4.5969e-020.3947image
chr19:52895194-52896714:-ESCAGSVA_HALLMARK_CHOLESTEROL_HOMEOSTASISEER3.3508e-03-0.3413image
chr19:52876554-52877094:-ESCAGSVA_HALLMARK_P53_PATHWAYEER4.3048e-020.2114image
ENSG00000182986.11,ZNF320ESCAGSVA_HALLMARK_HYPOXIAEAG3.0034e-020.1897image
chr19:52878276-52878916:-ESCAGSVA_HALLMARK_HYPOXIAEER5.6091e-040.3031image
ENSG00000182986.11,ZNF320GBMGSVA_HALLMARK_MYC_TARGETS_V2EAG2.8839e-04-0.2821image
chr19:52878276-52878916:-GBMGSVA_HALLMARK_BILE_ACID_METABOLISMEER1.2070e-040.3011image
chr19:52880041-52880529:-GBMGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER2.8764e-040.2979image
chr19:52876554-52877094:-GBMGSVA_HALLMARK_MYC_TARGETS_V2EER1.1492e-05-0.3520image
chr19:52878276-52878916:-HNSCGSVA_HALLMARK_COAGULATIONEER4.4835e-060.3389image
chr19:52880041-52880529:-HNSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER2.1206e-020.2020image
chr19:52876554-52877094:-HNSCGSVA_HALLMARK_FATTY_ACID_METABOLISMEER5.9966e-03-0.3047image
ENSG00000182986.11,ZNF320HNSCGSVA_HALLMARK_COAGULATIONEAG3.6257e-070.3488image
ENSG00000182986.11,ZNF320KICHGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG1.6182e-020.2996image
chr19:52878276-52878916:-KICHGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER3.4280e-020.2693image
chr19:52880041-52880529:-KICHGSVA_HALLMARK_ANDROGEN_RESPONSEEER1.3890e-04-0.4760image
chr19:52866667-52868433:-KIRCGSVA_HALLMARK_KRAS_SIGNALING_DNEER6.6647e-030.4383image
chr19:52876554-52877094:-KIRCGSVA_HALLMARK_ALLOGRAFT_REJECTIONEER8.3653e-040.1711image
ENSG00000182986.11,ZNF320KIRCGSVA_HALLMARK_ADIPOGENESISEAG1.3862e-05-0.2198image
chr19:52878276-52878916:-KIRCGSVA_HALLMARK_KRAS_SIGNALING_DNEER3.2156e-020.1098image
chr19:52882584-52885129:-KIRCGSVA_HALLMARK_DNA_REPAIREER1.8431e-020.2582image
chr19:52880041-52880529:-KIRCGSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITIONEER1.3219e-020.1274image
chr19:52895194-52896714:-KIRCGSVA_HALLMARK_MITOTIC_SPINDLEEER4.8059e-02-0.1565image
ENSG00000182986.11,ZNF320KIRPGSVA_HALLMARK_MYC_TARGETS_V2EAG6.2669e-030.1648image
chr19:52878276-52878916:-KIRPGSVA_HALLMARK_MYC_TARGETS_V2EER8.5361e-040.2018image
chr19:52882584-52885129:-KIRPGSVA_HALLMARK_DNA_REPAIREER2.6121e-020.2568image
chr19:52880041-52880529:-KIRPGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER6.4473e-080.3376image
chr19:52876554-52877094:-KIRPGSVA_HALLMARK_KRAS_SIGNALING_DNEER9.9634e-030.1614image
ENSG00000182986.11,ZNF320LAMLGSVA_HALLMARK_MYC_TARGETS_V2EAG6.0202e-03-0.2859image
chr19:52878276-52878916:-LAMLGSVA_HALLMARK_COMPLEMENTEER8.8478e-030.3198image
chr19:52876554-52877094:-LGGGSVA_HALLMARK_E2F_TARGETSEER6.9464e-06-0.2025image
ENSG00000182986.11,ZNF320LGGGSVA_HALLMARK_DNA_REPAIREAG1.2216e-13-0.3163image
chr19:52878276-52878916:-LGGGSVA_HALLMARK_E2F_TARGETSEER3.7378e-19-0.3843image
chr19:52880041-52880529:-LGGGSVA_HALLMARK_MITOTIC_SPINDLEEER2.3956e-09-0.2935image
chr19:52895194-52896714:-LGGGSVA_HALLMARK_APICAL_JUNCTIONEER4.4396e-03-0.5129image
chr19:52876554-52877094:-LIHCGSVA_HALLMARK_PEROXISOMEEER1.2129e-030.2981image
ENSG00000182986.11,ZNF320LIHCGSVA_HALLMARK_DNA_REPAIREAG3.1367e-03-0.2405image
chr19:52878276-52878916:-LIHCGSVA_HALLMARK_G2M_CHECKPOINTEER2.8027e-03-0.2601image
chr19:52880041-52880529:-LIHCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.3073e-030.3793image
chr19:52876554-52877094:-LUADGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER1.4561e-050.2304image
ENSG00000182986.11,ZNF320LUADGSVA_HALLMARK_COMPLEMENTEAG2.2324e-060.2156image
chr19:52878276-52878916:-LUADGSVA_HALLMARK_APOPTOSISEER1.6304e-060.2262image
chr19:52880041-52880529:-LUADGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER6.3961e-030.1379image
chr19:52895194-52896714:-LUADGSVA_HALLMARK_HYPOXIAEER1.0918e-040.6002image
chr19:52895194-52896714:-LUSCGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSEEER1.8040e-02-0.4884image
chr19:52876554-52877094:-LUSCGSVA_HALLMARK_INFLAMMATORY_RESPONSEEER3.6239e-060.3171image
ENSG00000182986.11,ZNF320LUSCGSVA_HALLMARK_ALLOGRAFT_REJECTIONEAG7.0183e-040.1851image
chr19:52878276-52878916:-LUSCGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEER2.6846e-020.1274image
chr19:52882584-52885129:-LUSCGSVA_HALLMARK_TGF_BETA_SIGNALINGEER3.9077e-03-0.5460image
chr19:52880041-52880529:-LUSCGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER1.6404e-050.2571image
chr19:52876554-52877094:-MESOGSVA_HALLMARK_APOPTOSISEER5.0802e-030.3662image
ENSG00000182986.11,ZNF320MESOGSVA_HALLMARK_IL2_STAT5_SIGNALINGEAG1.6905e-030.3566image
chr19:52878276-52878916:-MESOGSVA_HALLMARK_COAGULATIONEER4.5972e-040.4105image
ENSG00000182986.11,ZNF320OVGSVA_HALLMARK_PANCREAS_BETA_CELLSEAG2.9672e-060.2718image
chr19:52878276-52878916:-OVGSVA_HALLMARK_PANCREAS_BETA_CELLSEER6.1710e-060.2660image
chr19:52882584-52885129:-OVGSVA_HALLMARK_FATTY_ACID_METABOLISMEER1.2524e-020.3317image
chr19:52880041-52880529:-OVGSVA_HALLMARK_PANCREAS_BETA_CELLSEER1.7296e-040.2382image
chr19:52895194-52896714:-OVGSVA_HALLMARK_HEME_METABOLISMEER4.0622e-020.2151image
chr19:52876554-52877094:-OVGSVA_HALLMARK_ALLOGRAFT_REJECTIONEER3.8868e-050.2508image
chr19:52876554-52877094:-PAADGSVA_HALLMARK_MITOTIC_SPINDLEEER1.0438e-030.2705image
ENSG00000182986.11,ZNF320PAADGSVA_HALLMARK_NOTCH_SIGNALINGEAG2.0595e-030.2354image
chr19:52878276-52878916:-PAADGSVA_HALLMARK_COAGULATIONEER4.1136e-020.1637image
chr19:52880041-52880529:-PAADGSVA_HALLMARK_SPERMATOGENESISEER1.2911e-04-0.3283image
chr19:52876554-52877094:-PCPGGSVA_HALLMARK_DNA_REPAIREER4.1981e-02-0.1625image
ENSG00000182986.11,ZNF320PCPGGSVA_HALLMARK_ANDROGEN_RESPONSEEAG6.8141e-040.2558image
chr19:52878276-52878916:-PCPGGSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALINGEER1.0726e-030.2524image
chr19:52880041-52880529:-PCPGGSVA_HALLMARK_G2M_CHECKPOINTEER6.3559e-04-0.3533image
chr19:52876554-52877094:-PRADGSVA_HALLMARK_MYC_TARGETS_V2EER2.6757e-03-0.1397image
ENSG00000182986.11,ZNF320PRADGSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITIONEAG4.6981e-030.1268image
chr19:52878276-52878916:-PRADGSVA_HALLMARK_UV_RESPONSE_UPEER7.5345e-040.1525image
chr19:52880041-52880529:-PRADGSVA_HALLMARK_MITOTIC_SPINDLEEER6.7711e-12-0.3350image
ENSG00000182986.11,ZNF320READGSVA_HALLMARK_UV_RESPONSE_UPEAG2.3774e-020.2409image
chr19:52878276-52878916:-READGSVA_HALLMARK_UV_RESPONSE_UPEER2.7226e-030.3269image
chr19:52880041-52880529:-READGSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALINGEER1.7919e-02-0.2803image
chr19:52880041-52880529:-SARCGSVA_HALLMARK_TGF_BETA_SIGNALINGEER1.4621e-02-0.1971image
chr19:52876554-52877094:-SARCGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEER9.9461e-04-0.2427image
ENSG00000182986.11,ZNF320SARCGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG2.0156e-040.2427image
chr19:52878276-52878916:-SARCGSVA_HALLMARK_APOPTOSISEER5.8343e-040.2327image
chr19:52876554-52877094:-SKCMGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER2.5348e-060.3064image
ENSG00000182986.11,ZNF320SKCMGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG4.8179e-090.3227image
chr19:52878276-52878916:-SKCMGSVA_HALLMARK_BILE_ACID_METABOLISMEER7.8311e-040.1978image
chr19:52880041-52880529:-SKCMGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER1.3541e-080.3515image
chr19:52876554-52877094:-STADGSVA_HALLMARK_ALLOGRAFT_REJECTIONEER2.4353e-030.1960image
ENSG00000182986.11,ZNF320STADGSVA_HALLMARK_HYPOXIAEAG1.0780e-030.1800image
chr19:52878276-52878916:-STADGSVA_HALLMARK_ESTROGEN_RESPONSE_LATEEER5.4058e-040.1979image
chr19:52882584-52885129:-STADGSVA_HALLMARK_INFLAMMATORY_RESPONSEEER2.5046e-030.4705image
chr19:52880041-52880529:-STADGSVA_HALLMARK_MITOTIC_SPINDLEEER4.5584e-04-0.2008image
chr19:52895194-52896714:-STADGSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALINGEER1.1372e-020.1893image
ENSG00000182986.11,ZNF320TGCTGSVA_HALLMARK_KRAS_SIGNALING_UPEAG2.1185e-030.2458image
chr19:52878276-52878916:-TGCTGSVA_HALLMARK_G2M_CHECKPOINTEER7.7545e-06-0.3654image
chr19:52880041-52880529:-TGCTGSVA_HALLMARK_MITOTIC_SPINDLEEER1.0088e-04-0.3272image
chr19:52876554-52877094:-TGCTGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER9.2794e-030.2274image
ENSG00000182986.11,ZNF320THCAGSVA_HALLMARK_INFLAMMATORY_RESPONSEEAG3.5932e-080.2435image
chr19:52878276-52878916:-THCAGSVA_HALLMARK_XENOBIOTIC_METABOLISMEER1.9311e-030.1415image
chr19:52880041-52880529:-THCAGSVA_HALLMARK_PROTEIN_SECRETIONEER1.5832e-05-0.2097image
chr19:52876554-52877094:-THCAGSVA_HALLMARK_ALLOGRAFT_REJECTIONEER1.5171e-040.1748image
chr19:52876554-52877094:-THYMGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEER2.9723e-03-0.3114image
ENSG00000182986.11,ZNF320THYMGSVA_HALLMARK_BILE_ACID_METABOLISMEAG2.0405e-020.2239image
chr19:52880041-52880529:-THYMGSVA_HALLMARK_FATTY_ACID_METABOLISMEER1.5210e-020.3022image
chr19:52876554-52877094:-UCECGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER9.5350e-030.2090image
ENSG00000182986.11,ZNF320UCECGSVA_HALLMARK_DNA_REPAIREAG1.9166e-02-0.1780image
chr19:52878276-52878916:-UCECGSVA_HALLMARK_ESTROGEN_RESPONSE_LATEEER8.3335e-050.3006image
chr19:52880041-52880529:-UCECGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEER8.8915e-03-0.2227image
chr19:52876554-52877094:-UCSGSVA_HALLMARK_IL2_STAT5_SIGNALINGEER3.1623e-040.5128image
ENSG00000182986.11,ZNF320UCSGSVA_HALLMARK_HYPOXIAEAG6.1789e-030.3714image
chr19:52878276-52878916:-UCSGSVA_HALLMARK_XENOBIOTIC_METABOLISMEER2.8331e-020.3042image
chr19:52880041-52880529:-UCSGSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALINGEER1.4632e-020.4037image
chr19:52876554-52877094:-UVMGSVA_HALLMARK_BILE_ACID_METABOLISMEER8.5795e-040.6240image
ENSG00000182986.11,ZNF320UVMGSVA_HALLMARK_KRAS_SIGNALING_DNEAG1.2524e-030.4567image


Top

7. Enriched editing regions and drugs for ZNF320


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
ENSG00000182986.11,ZNF320ACCBortezomibEAG2.1229e-020.2770image
chr19:52878276-52878916:-ACCAZD8055EER4.8363e-020.2560image
chr19:52880041-52880529:-ACCCyclopamineEER2.1187e-020.3634image
ENSG00000182986.11,ZNF320BLCACMKEAG6.4671e-06-0.2296image
chr19:52878276-52878916:-BLCACMKEER6.3554e-10-0.3175image
chr19:52882584-52885129:-BLCAATRAEER1.7601e-020.2370image
chr19:52880041-52880529:-BLCAKU.55933EER4.4299e-12-0.3828image
chr19:52895194-52896714:-BLCAGefitinibEER8.1497e-06-0.6058image
chr19:52876554-52877094:-BLCACMKEER1.4592e-11-0.3848image
ENSG00000182986.11,ZNF320BRCAGSK.650394EAG7.7852e-070.1509image
chr19:52878276-52878916:-BRCAABT.263EER1.1287e-080.1765image
chr19:52880041-52880529:-BRCAA.770041EER4.0765e-15-0.2495image
chr19:52895194-52896714:-BRCAEmbelinEER7.3917e-040.3438image
chr19:52876554-52877094:-BRCACGP.082996EER6.8327e-05-0.1266image
chr19:52878276-52878916:-CESCCGP.082996EER1.0409e-02-0.2046image
chr19:52880041-52880529:-CESCGefitinibEER1.9445e-04-0.3261image
chr19:52876554-52877094:-CESCCGP.082996EER1.1413e-02-0.2393image
ENSG00000182986.11,ZNF320CESCAICAREAG2.0233e-05-0.3188image
chr19:52876554-52877094:-CHOLDMOGEER1.4688e-02-0.4210image
ENSG00000182986.11,ZNF320CHOLCamptothecinEAG2.1459e-020.3931image
chr19:52880041-52880529:-CHOLBMS.536924EER4.7848e-02-0.3772image
chr19:52876554-52877094:-COADAZD8055EER1.0845e-03-0.2867image
ENSG00000182986.11,ZNF320COADGefitinibEAG4.6122e-08-0.3398image
chr19:52878276-52878916:-COADAICAREER5.3001e-03-0.1918image
chr19:52880041-52880529:-COADGefitinibEER5.5199e-06-0.3106image
chr19:52895194-52896714:-COADImatinibEER3.6944e-020.4691image
chr19:52880041-52880529:-ESCAKIN001.135EER3.8209e-03-0.2632image
chr19:52882584-52885129:-ESCAElesclomolEER2.6398e-02-0.4349image
chr19:52895194-52896714:-ESCALenalidomideEER7.2837e-04-0.3892image
chr19:52876554-52877094:-ESCAAxitinibEER1.6520e-030.3253image
ENSG00000182986.11,ZNF320ESCABexaroteneEAG1.1270e-02-0.2208image
chr19:52878276-52878916:-ESCAAICAREER1.6093e-03-0.2782image
ENSG00000182986.11,ZNF320GBMGSK.650394EAG1.6105e-060.3676image
chr19:52878276-52878916:-GBMLapatinibEER1.8481e-05-0.3335image
chr19:52880041-52880529:-GBMCGP.082996EER8.8669e-06-0.3608image
chr19:52876554-52877094:-GBMGSK.650394EER7.2780e-060.3594image
chr19:52878276-52878916:-HNSCCGP.60474EER3.4740e-05-0.3075image
chr19:52880041-52880529:-HNSCAZD.0530EER3.8777e-04-0.3066image
chr19:52876554-52877094:-HNSCLFM.A13EER2.8783e-03-0.3291image
ENSG00000182986.11,ZNF320HNSCAZD.0530EAG3.4597e-06-0.3207image
ENSG00000182986.11,ZNF320KICHMetforminEAG1.7684e-02-0.2957image
chr19:52878276-52878916:-KICHABT.263EER2.7803e-020.2795image
chr19:52880041-52880529:-KICHBryostatin.1EER5.5350e-04-0.4362image
chr19:52866667-52868433:-KIRCCisplatinEER5.7277e-030.4455image
chr19:52876554-52877094:-KIRCCisplatinEER1.3158e-06-0.2458image
ENSG00000182986.11,ZNF320KIRCJNK.Inhibitor.VIIIEAG4.9460e-11-0.3272image
chr19:52878276-52878916:-KIRCMetforminEER2.2258e-030.1562image
chr19:52882584-52885129:-KIRCAG.014699EER5.9561e-030.2994image
chr19:52880041-52880529:-KIRCEpothilone.BEER6.8683e-070.2521image
chr19:52895194-52896714:-KIRCAZD6482EER2.8035e-030.2348image
ENSG00000182986.11,ZNF320KIRPLFM.A13EAG2.0006e-030.1859image
chr19:52878276-52878916:-KIRPLFM.A13EER2.1666e-030.1858image
chr19:52880041-52880529:-KIRPCCT007093EER2.7547e-110.4096image
chr19:52895194-52896714:-KIRPAG.014699EER9.3222e-03-0.2789image
chr19:52876554-52877094:-KIRPEHT.1864EER1.9545e-030.1934image
ENSG00000182986.11,ZNF320LAMLDoxorubicinEAG8.3948e-030.2748image
chr19:52878276-52878916:-LAMLAG.014699EER9.5074e-030.3170image
chr19:52876554-52877094:-LGGBMS.708163EER5.6982e-10-0.2767image
ENSG00000182986.11,ZNF320LGGBMS.708163EAG8.3474e-18-0.3634image
chr19:52878276-52878916:-LGGGemcitabineEER3.5111e-230.4224image
chr19:52880041-52880529:-LGGEmbelinEER8.0613e-090.2840image
chr19:52895194-52896714:-LGGBleomycinEER1.0081e-02-0.4701image
chr19:52876554-52877094:-LIHCGSK.650394EER5.1597e-040.3188image
ENSG00000182986.11,ZNF320LIHCEtoposideEAG9.6283e-050.3140image
chr19:52878276-52878916:-LIHCGefitinibEER9.1975e-04-0.2951image
chr19:52880041-52880529:-LIHCDoxorubicinEER1.5691e-020.2899image
chr19:52876554-52877094:-LUADGemcitabineEER2.0847e-05-0.2263image
ENSG00000182986.11,ZNF320LUADAICAREAG4.6268e-06-0.2089image
chr19:52878276-52878916:-LUADCI.1040EER1.9878e-05-0.2019image
chr19:52880041-52880529:-LUADCI.1040EER4.9907e-03-0.1419image
chr19:52895194-52896714:-LUSCCisplatinEER1.1814e-020.5155image
chr19:52876554-52877094:-LUSCCI.1040EER4.4411e-06-0.3143image
ENSG00000182986.11,ZNF320LUSCMG.132EAG4.8898e-05-0.2213image
chr19:52878276-52878916:-LUSCAZD7762EER2.9796e-03-0.1704image
chr19:52882584-52885129:-LUSCGDC.0449EER3.4511e-04-0.6479image
chr19:52880041-52880529:-LUSCCI.1040EER1.2165e-03-0.1945image
chr19:52876554-52877094:-MESOCGP.082996EER2.2884e-02-0.3010image
ENSG00000182986.11,ZNF320MESODMOGEAG6.1075e-03-0.3138image
chr19:52878276-52878916:-MESOBIRB.0796EER6.2676e-040.4016image
ENSG00000182986.11,ZNF320OVAZD.2281EAG3.7334e-04-0.2090image
chr19:52878276-52878916:-OVAZD.2281EER8.7918e-07-0.2889image
chr19:52882584-52885129:-OVGW.441756EER5.4953e-04-0.4472image
chr19:52880041-52880529:-OVA.770041EER9.4788e-06-0.2793image
chr19:52876554-52877094:-OVEmbelinEER7.4262e-050.2418image
chr19:52876554-52877094:-PAADFTI.277EER4.2970e-02-0.1689image
ENSG00000182986.11,ZNF320PAADAxitinibEAG1.8646e-030.2397image
chr19:52880041-52880529:-PAADAZD6244EER1.2416e-03-0.2792image
chr19:52876554-52877094:-PCPGDMOGEER8.8415e-03-0.2083image
ENSG00000182986.11,ZNF320PCPGA.443654EAG6.3860e-050.2992image
chr19:52878276-52878916:-PCPGBI.2536EER8.0084e-030.2058image
chr19:52880041-52880529:-PCPGAZD6482EER4.2177e-020.2147image
chr19:52876554-52877094:-PRADEpothilone.BEER2.5954e-030.1401image
ENSG00000182986.11,ZNF320PRADJNK.Inhibitor.VIIIEAG1.6732e-06-0.2131image
chr19:52878276-52878916:-PRADEpothilone.BEER2.4729e-020.1020image
chr19:52880041-52880529:-PRADBMS.536924EER2.7153e-07-0.2543image
ENSG00000182986.11,ZNF320READLapatinibEAG1.9108e-03-0.3264image
chr19:52878276-52878916:-READLapatinibEER1.1593e-03-0.3526image
chr19:52880041-52880529:-READCyclopamineEER5.5052e-04-0.3999image
chr19:52880041-52880529:-SARCGefitinibEER1.6364e-02-0.1938image
chr19:52876554-52877094:-SARCDasatinibEER1.5483e-05-0.3160image
ENSG00000182986.11,ZNF320SARCAICAREAG1.8270e-04-0.2443image
chr19:52878276-52878916:-SARCAP.24534EER3.0716e-03-0.2010image
chr19:52876554-52877094:-SKCMJW.7.52.1EER1.5799e-06-0.3124image
ENSG00000182986.11,ZNF320SKCMDoxorubicinEAG6.6757e-060.2511image
chr19:52878276-52878916:-SKCMAZD6244EER1.1149e-04-0.2269image
chr19:52880041-52880529:-SKCMAZD6244EER1.6580e-05-0.2703image
chr19:52876554-52877094:-STADAZD.2281EER9.2684e-07-0.3130image
ENSG00000182986.11,ZNF320STADBexaroteneEAG3.0166e-04-0.1986image
chr19:52878276-52878916:-STADIPA.3EER4.7705e-030.1623image
chr19:52882584-52885129:-STADBMS.708163EER1.2596e-02-0.3959image
chr19:52880041-52880529:-STADBMS.509744EER2.7018e-05-0.2394image
chr19:52895194-52896714:-STADCyclopamineEER2.0760e-02-0.1732image
ENSG00000182986.11,ZNF320TGCTAZD6244EAG1.8771e-03-0.2486image
chr19:52878276-52878916:-TGCTAZ628EER3.2738e-06-0.3791image
chr19:52880041-52880529:-TGCTGDC.0449EER4.1018e-05-0.3441image
chr19:52876554-52877094:-TGCTAZ628EER9.1608e-03-0.2278image
ENSG00000182986.11,ZNF320THCAAICAREAG1.9689e-07-0.2303image
chr19:52878276-52878916:-THCAIPA.3EER6.1847e-030.1251image
chr19:52880041-52880529:-THCAEmbelinEER1.0478e-090.2931image
chr19:52876554-52877094:-THCAGefitinibEER6.3278e-06-0.2077image
chr19:52876554-52877094:-THYMCytarabineEER3.6777e-040.3694image
ENSG00000182986.11,ZNF320THYMBI.2536EAG3.5141e-040.3392image
chr19:52878276-52878916:-THYMCMKEER4.7838e-040.3463image
chr19:52880041-52880529:-THYMEmbelinEER2.2556e-030.3751image
chr19:52876554-52877094:-UCECA.770041EER2.6012e-18-0.6302image
ENSG00000182986.11,ZNF320UCECEHT.1864EAG1.0101e-040.2913image
chr19:52878276-52878916:-UCECAxitinibEER3.8916e-030.2229image
chr19:52880041-52880529:-UCECA.770041EER6.1253e-03-0.2331image
chr19:52876554-52877094:-UCSCGP.60474EER1.3968e-03-0.4621image
ENSG00000182986.11,ZNF320UCSBexaroteneEAG1.9642e-02-0.3196image
chr19:52878276-52878916:-UCSGNF.2EER9.7160e-03-0.3554image
chr19:52880041-52880529:-UCSCCT007093EER3.2308e-020.3575image
chr19:52876554-52877094:-UVMBAY.61.3606EER4.1280e-040.6520image
ENSG00000182986.11,ZNF320UVMDoxorubicinEAG9.7084e-040.4657image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType